Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
NCT ID: NCT00168740
Last Updated: 2005-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
150 participants
INTERVENTIONAL
1995-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rituximab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* CD20-positive lymphoma
* Progressive, measurable disease
* Sign informed consent
* 3 weeks beyond standard therapy
* Good performance status
* Adequate hematologic, renal, and hepatic function
Exclusion Criteria
* Lesions greater than or equal to 10 cm in diameter
* CNS lymphoma
* AIDS-related lymphoma
* Pleural effusions or ascites secondary to lymphoma
* Active, opportunistic infection
* Serious nonmalignant disease
* Prior investigational therapies, including prior anti-CD20 therapy
* Recent major surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antonio J. Grillo-Lopez, M.D.
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
City of Hope Natioal Medical Center
Duarte, California, United States
Scripps Memorial Hospital
La Jolla, California, United States
UCSD Stem Cell Laboratory
La Jolla, California, United States
Hoag Hospital
Newport Beach, California, United States
Sutter Cancer Center
Sacramento, California, United States
Sidney Kimmel Cancer Center
San Diego, California, United States
University of California, San Francisco
San Francisco, California, United States
Stanford University Medical Center
Stanford, California, United States
Kaiser Permanente Medical Center
Vallejo, California, United States
Rocky Mountain Cancer Center
Denver, Colorado, United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Robert H. Lurie Cancer Center, Northwestern University
Chicago, Illinois, United States
University of Iowa General Hospital
Iowa City, Iowa, United States
University of Kentucky Medical Center
Lexington, Kentucky, United States
Louisiana State University
Shreveport, Louisiana, United States
University of Maryland Cancer Center
Baltimore, Maryland, United States
Michigan State University
East Lansing, Michigan, United States
St. Louis University Medical Center
St Louis, Missouri, United States
Roswell Park Cancer Center
Buffalo, New York, United States
University of Rochester Cancer Center
Rochester, New York, United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
The West Clinic, P.C.
Memphis, Tennessee, United States
Texas Oncology, P.A.
Dallas, Texas, United States
M.D. Anderson Cancer Center
Houston, Texas, United States
University of Texas Health Sciences Center
San Antonio, Texas, United States
University of Virginia
Charlottesville, Virginia, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Ottawa General Hospital
Ottawa, Ontario, Canada
Toronto-Sunnybrook Regional Cancer Center
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33. doi: 10.1200/JCO.1998.16.8.2825.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDEC-102-05
Identifier Type: -
Identifier Source: org_study_id